



Release No 315

18 December 2007

Share Buyback in H. Lundbeck A/S

Acting on its authorization to acquire up to 10% of its shares the H. Lundbeck Supervisory Board has resolved to initiate a share buyback program. Under the program H. Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 on 17th August 2005.

During any one single trading day a maximum of 25% of the average daily trading volume of Lundbeck shares on the Copenhagen Stock Exchange, calculated over 20 days prior to each trading date, will be bought back, as the share buyback program is implemented in accordance with the provisions of the European Commission's regulation no. 2273/2003 of December 22, 2003.

At least once every seven trading days, Lundbeck will issue an announcement in respect of the transactions made under the program.

The following transactions have been made under the program:

	No. of shares	Average purchase price (DKK)	Transaction value (DKK)
Accumulated, last announcement	25,168,102	135.7029	3,415,384,166
10 December 2007	36,888	147.0857	5,425,696.08
11 December 2007	--	--	--
12 December 2007	14,514	149.3588	2,167,793.68
13 December 2007	112,915	147.2168	16,622,986.01
14 December 2007	--	--	--
17 December 2007	118,801	148.9786	17,698,805.72
18 December 2007	119,059	145.9405	17,375,533.60
Accumulated under the program	25,570,279	135.8873	3,474,674,981



Following the above buyback it is hereby announced that Lundbeck owns a total of 5,867,644 own shares at a nominal value of DKK 5, equal to 3.09% of the total number of 207,279,631 shares.

The content of this release will have no influence on the Lundbeck Group's financial result for 2007.

Lundbeck contacts

Investors:

Jacob Tolstrup
Director, Corporate Reporting
+45 36 43 30 79

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26

Media:

Anders Schroll
Head of Communication
+45 36 43 20 81

Stock Exchange Release No 315 – 18 December 2007

About Lundbeck

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com